Literature DB >> 15529163

Characterizing biological products and assessing comparability following manufacturing changes.

Arthur J Chirino1, Anthony Mire-Sluis.   

Abstract

Changes in production methods of a biological product may necessitate an assessment of comparability to ensure that these manufacturing changes have not affected the safety, identity, purity, or efficacy of the product. Depending on the nature of the protein or the change, this assessment consists of a hierarchy of sequential tests in analytical testing, preclinical animal studies and clinical studies. Differences in analytical test results between pre- and post-change products may require functional testing to establish the biological or clinical significance of the observed difference. An underlying principle of comparability is that under certain conditions, protein products may be considered comparable on the basis of analytical testing results alone. However, the ability to compare biological materials is solely dependent on the tests used, since no single analytical method is able to compare every aspect of protein structure or function. The advantages and disadvantages of any given method depends on the protein property being characterized.

Mesh:

Substances:

Year:  2004        PMID: 15529163     DOI: 10.1038/nbt1030

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


  66 in total

Review 1.  Emerging technologies for making glycan-defined glycoproteins.

Authors:  Lai-Xi Wang; Joseph V Lomino
Journal:  ACS Chem Biol       Date:  2011-12-14       Impact factor: 5.100

2.  An empirical phase diagram approach to investigate conformational stability of "second-generation" functional mutants of acidic fibroblast growth factor-1.

Authors:  Mohammad A Alsenaidy; Tingting Wang; Jae Hyun Kim; Sangeeta B Joshi; Jihun Lee; Michael Blaber; David B Volkin; C Russell Middaugh
Journal:  Protein Sci       Date:  2012-02-06       Impact factor: 6.725

3.  Characterization of the basic charge variants of a human IgG1: effect of copper concentration in cell culture media.

Authors:  Timothy Kaschak; Daniel Boyd; Franklin Lu; Gayle Derfus; Brian Kluck; Bartek Nogal; Craig Emery; Christie Summers; Kai Zheng; Robert Bayer; Ashraf Amanullah; Boxu Yan
Journal:  MAbs       Date:  2011-11-01       Impact factor: 5.857

4.  Physicochemical characterization of complex drug substances: evaluation of structural similarities and differences of protamine sulfate from various sources.

Authors:  David Awotwe-Otoo; Cyrus Agarabi; David Keire; Sau Lee; Andre Raw; Lawrence Yu; Muhammad J Habib; Mansoor A Khan; Rakhi B Shah
Journal:  AAPS J       Date:  2012-06-08       Impact factor: 4.009

Review 5.  Cell culture processes for monoclonal antibody production.

Authors:  Feng Li; Natarajan Vijayasankaran; Amy Yijuan Shen; Robert Kiss; Ashraf Amanullah
Journal:  MAbs       Date:  2010-09-01       Impact factor: 5.857

Review 6.  Role of analytical ultracentrifugation in assessing the aggregation of protein biopharmaceuticals.

Authors:  Steven A Berkowitz
Journal:  AAPS J       Date:  2006-09-22       Impact factor: 4.009

7.  N-terminal glutamate to pyroglutamate conversion in vivo for human IgG2 antibodies.

Authors:  Y Diana Liu; Andrew M Goetze; Randal B Bass; Gregory C Flynn
Journal:  J Biol Chem       Date:  2011-01-31       Impact factor: 5.157

8.  High-throughput N-glycan screening method for therapeutic antibodies using a microchip-based DNA analyzer: a promising methodology for monitoring monoclonal antibody N-glycosylation.

Authors:  Mitsuhiro Kinoshita; Kazuki Nakajima; Sachio Yamamoto; Shigeo Suzuki
Journal:  Anal Bioanal Chem       Date:  2021-06-02       Impact factor: 4.142

9.  Enhancing Sensitivity of Liquid Chromatography-Mass Spectrometry of Peptides and Proteins Using Supercharging Agents.

Authors:  Michael Nshanian; Rajeswari Lakshmanan; Hao Chen; Rachel R Ogorzalek Loo; Joseph A Loo
Journal:  Int J Mass Spectrom       Date:  2017-12-24       Impact factor: 1.986

10.  A bayesian approach for quantifying trace amounts of antibody aggregates by sedimentation velocity analytical ultracentrifugation.

Authors:  Patrick H Brown; Andrea Balbo; Peter Schuck
Journal:  AAPS J       Date:  2008-09-24       Impact factor: 4.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.